文章摘要
陈 琳,黄 洁,陈滢洁,沈 君,王 晶.肾康注射液联合羟苯磺酸钙胶囊对PNS并发AKI患者肾功能、凝血功能及炎性因子的影响[J].,2021,(8):1456-1459
肾康注射液联合羟苯磺酸钙胶囊对PNS并发AKI患者肾功能、凝血功能及炎性因子的影响
Effect of Shenkang Injection Combined with Calcium Dobesilate Capsule on Renal Function, Coagulation Function and Inflammatory Factors in Patients with PNS Complicated with AKI
投稿时间:2020-10-07  修订日期:2020-10-30
DOI:10.13241/j.cnki.pmb.2021.08.012
中文关键词: 肾康注射液  羟苯磺酸钙胶囊  原发性肾病综合征  急性肾损伤  肾功能  凝血功能  炎性因子
英文关键词: Shenkang injection  Calcium dobesilate capsule  Primary nephrotic syndrome  Acute kidney injury  Renal function  Coagulation function  Inflammatory factors
基金项目:上海市卫生和计划生育委员会科研项目(201440272)
作者单位E-mail
陈 琳 上海交通大学医学院附属第九人民医院肾脏内科 上海 200011 chengpanlu0699990@163.com 
黄 洁 上海交通大学医学院附属第九人民医院肾脏内科 上海 200011  
陈滢洁 上海交通大学医学院附属第九人民医院肾脏内科 上海 200011  
沈 君 上海交通大学医学院附属第九人民医院肾脏内科 上海 200011  
王 晶 复旦大学附属中山医院肾内科 上海 200032  
摘要点击次数: 28
全文下载次数: 28
中文摘要:
      摘要 目的:探讨肾康注射液联合羟苯磺酸钙胶囊对原发性肾病综合征(PNS)并发急性肾损伤(AKI)患者肾功能、凝血功能及炎性因子的影响。方法:选取2018年4月~2019年11月期间我院收治的134例PNS合并AKI患者,随机分为对照组(常规治疗基础上予以羟苯磺酸钙胶囊治疗)和联合组(对照组基础上予以肾康注射液治疗),各67例。治疗14 d后,对比两组患者疗效、肾功能指标[尿素氮(BUN)、血肌酐(Scr)、白蛋白(Alb)]、凝血功能指标[凝血酶时间(TT)、凝血酶原时间(PT)、活化部分凝血酶原时间(APTT)、纤维蛋白原(FIB)]及炎性因子[白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)],记录两组不良反应情况。结果:联合组治疗14d后的临床总有效率高于对照组(P<0.05)。治疗14 d后,两组PT、APTT、TT、FIB、Scr、BUN、IL-6、TNF-α、CRP均较治疗前下降,且联合组低于对照组(P<0.05)。治疗14 d后,两组Alb升高,且联合组高于对照组(P<0.05)。对照组、联合组的不良反应总发生率对比未见统计学差异(P>0.05)。结论:相较于羟苯磺酸钙胶囊单药治疗,PNS合并AKI患者在羟苯磺酸钙胶囊的基础上联合肾康注射液治疗,可有效减轻肾功能损害,改善凝血功能,降低炎性因子水平,疗效明显,且未增加严重不良反应。
英文摘要:
      ABSTRACT Objective: To investigate the effect of Shenkang injection combined with calcium dobesilate capsule on renal function, coagulation function and inflammatory factors in patients with primary nephrotic syndrome (PNS) complicated with acute kidney injury (AKI). Methods: From April 2018 to November 2019, 134 patients with PNS complicated with AKI in our hospital were selected, they were randomly divided into control group (treated with calcium dobesilate capsules on the basis of conventional treatment) and combined group (treated with Shenkang injection on the basis of control group), 67 cases in each group. 14 days after treatment, the curative effect, renal function indexes [urea nitrogen (BUN), serum creatinine (Scr), albumin (Alb)], coagulation function indexes [thrombin time (TT), prothrombin time (PT), activated partial prothrombin time (APTT), fibrinogen (FIB)] and inflammatory factors [interleukin-6 (IL-6), tumor necrosis factor-α(TNF-α), C-reactive protein(CRP)] were compared between the two groups. The adverse reactions of the two groups were recorded. Results: 14 days after treatment, the total effective rate of the combined group was higher than that of the control group(P<0.05). 14 days after treatment, PT, APTT, TT, FIB, Scr, BUN, IL-6, TNF-α and CRP of the two groups decreased compared with those before treatment, and the combined group was lower than the control group (P<0.05). 14 days after treatment, Alb of the two groups increased, and the combined group was higher than the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the control group and the combined group(P>0.05). Conclusion: Compared with calcium dobesilate capsule single drug treatment, patients with PNS complicated with AKI on the basis of calcium dobesilate capsules combined with Shenkang injection can effectively reduce renal function damage, improve coagulation function, reduce the level of inflammatory factors, with obvious curative effect, and no increase of serious adverse reactions.
查看全文   查看/发表评论  下载PDF阅读器
关闭